A Randomized Double Blind Placebo Controlled Study Of Celecoxib Add-On Therapy In Schizophrenia

King Georges Medical University0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Diagnosis of Schizophrenia as per ICD-10, DCR (Diagnostic Criteria for reasearch)
•2.Patients aged between 18 to 50 years
•3.Not on any antipsychotic for last three months.
•4.Total duration of illness less than ten years.
•5.Availability of a reliable informant
•6.Written informed consent from the patient and/or informant.

•1.Positive and Negative Syndrome Scale (PANSS) score <80 or >120.
•2.Presence of any other major psychiatric disorder, except nicotine dependence.
•3.Patients with pre-existing mental subnormality
•4.Patients at risk for harm to self or others.
•5.Established treatment resistance for schizophrenia.
•6.Clinical situations requiring alternative drugs or interventions eg injectable antipsychotics, ECTs, change of therapy etc., or worsening of symptoms.
•7.Patients having history of ischemic heart disease/ hypertension/ liver disease/ cardiac failure/ cerebrovascular disease/ immunological disorders/ obesity/ diabetes or any other disease that may alter serum interleukin levels.
•8.Any clinically significant abnormality in routine investigations, ( Hb, TLC, DLC, RBS, S.Urea, S.Creatinine, LFT)
•9.Patient on any other concomitant drugs that might alter serum interleukin levels.
•10.Pregnant and lactating females.
•11.Patients developing any illness during the course of study that might change the serum interleukin levels.
•12.Withdrawal of consent.
•13.Safety concerns.

发起方

King Georges Medical University